ALNYLAM PHARMACEUTICALS, INC. (ALNY) Financials
Annual revenue, profitability and per-share results for ALNYLAM PHARMACEUTICALS, INC., as reported in SEC filings.
Revenue • FY2025
$3.71B
▲ 65.2%YoY
Net income • FY2025
$313.75M
▲ 212.8%YoY
Gross margin • FY2025
81.8%
Diluted EPS • FY2025
$2.33
▲ 206.9%YoY
Annual income statement
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $3.71B | $313.75M | $3.04B | $2.33 | $465.38M | 13.5% | +65.2% |
| FY2024 | $2.25B | -$278.16M | $1.94B | $-2.18 | -$42.59M | -7.9% | +23.0% |
| FY2023 | $1.83B | -$440.24M | $1.56B | $-3.52 | $41.95M | -15.4% | +76.2% |
| FY2022 | $1.04B | -$1.13B | $897.24M | $-9.30 | -$613.33M | -75.7% | +22.9% |
Figures as reported in ALNYLAM PHARMACEUTICALS, INC.'s 10-K filings on SEC EDGAR. Fiscal years may differ from calendar years.
Financials for companies related to ALNY
Never miss a ALNY filing.
Get an email when ALNY files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Source: SEC EDGAR.